With less than 14% of Phase I to III drug candidates winning FDA approval, unforeseen roadblocks can derail even the most promising clinical research programs.
Communicators will discover that the secret of ushering curative treatments through cost-value review bodies and regulatory agencies is to demonstrate the value to the whole person.